Skip to main content

Advertisement

Table 2 Baseline HPV-16 E6/E7 median OD1 ratios2 and ranges by risk factors, and histopathologic characteristics

From: Human papillomavirus serologic follow-up response and relationship to survival in head and neck cancer: a case-comparison study

Characteristics HPV-16 E6 HPV-16 E7 HPV-16 E6 and/or E7
  Positive (n = 22) Positive (n = 20) Positive (n = 26)
  n (%) Median (Range) n (%) Median (Range) n (%) Median (Range)
Gender       
   Male 15 (22.4) 5.2 (1.8-11.3) 15 (22.4) 5.5 (1.3-37.2) 17 (25.4) 5.9 (1.3-37.2)
   Female 7 (16.7) 4.7 (1.2-5.7) 5 (11.9) 2.1 (1.01-14.7) 9 (21.4) 4.7 (1.2-14.7)
Age Group       
   ≤ 55 years 14 (31.8) 5.3 (1.2-10.8) 12 (27.3) 4.9 (1.01-37.2) 15 (34.1) 5.5 (4.2-37.2)
   > 55 years 8 (12.3) 5.0 (1.8-11.3) 8 (12.3) 5.7 (1.3-14.7) 11 (16.9) 5.8 (1.2-14.7)
Number of Partners       
   0-2 7 (16.7) 4.7 (1.2-7.3) 6 (14.3) 1.8 (1.01-37.2) 9 (21.4) 4.6 (1.2-37.2)
   3-9 5 (17.9) 5.9 (1.8-9.0) 4 (14.3) 4.9 (3.8-11.0) 5 (17.9) 7.3 (5.2-11.0)
   ≥ 10 9 (29.0) 5.0 (2.5-11.3) 8 (25.8) 5.5 (1.5-9.3) 10 (32.3) 5.6 (4.2-11.3)
Pack years       
   Never 6 (20.7) 5.0 (1.2-9.0) 4 (13.8) 5.0 (3.8-9.3) 6 (20.7) 5.6 (1.2-9.3)
   ≤ 30 12 (46.2) 5.1 (2.5-10.8) 10 (38.5) 5.5 (1.01-37.2) 12 (46.2) 5.7 (4.3-37.2)
   > 30 4 (7.4) 5.3 (1.8-11.3) 6 (11.1) 6.8 (1.3-14.7) 8 (14.8) 5.3 (1.3-14.7)
Drinks per Week       
   Never 6 (17.6) 5.1 (1.2-7.8) 5 (14.7) 6.1 (1.3-9.3) 7 (20.6) 5.9 (1.2-9.3)
   ≤ 21 10 (22.7) 5.3 (2.5-10.8) 9 (20.5) 4.3 (1.01-37.2) 12 (27.3) 5.6 (2.1-37.2)
   > 21 6 (19.4) 4.7 (1.8-11.3) 6 (19.4) 5.0 (1.5-11.0) 7 (22.6) 5.2 (4.2-11.3)
Tumor Site       
   Oropharynx 20 (74.1) 5.1 (1.8-11.3) 16 (59.3) 5.7 (1.01-37.2) 20 (74.1) 5.9 (4.3-37.2)
   Oral Cavity 2 (2.7) 2.6 (1.2-4.1)3 2 (2.7) 9.5 (4.2-14.7)3 4 (5.5) 4.2 (1.2-14.7)
   Larynx\hypopharynx 0 (0.0) - 2 (22.2) 1.7 (1.3-2.1)3 2 (22.2) 1.7 (1.3-2.1)3
Stage       
   I/II 2 (5.0) 2.6 (1.2-4.1)3 1 (2.5) 1.3 (1.3-1.3)3 3 (7.5) 1.3 (1.2-4.1)*
   III/IV 20 (29.0) 5.1 (1.8-11.3) 19 (27.5) 5.5 (1.01-37.2) 23 (33.3) 5.8 (2.1-37.2)*
Tumor Size       
   T0-T2 18 (28.6) 4.9 (1.2-11.3)* 13 (20.6) 5.5 (1.01-37.2) 19 (30.2) 5.5 (1.2-37.2)
   T3-T4 4 (9.1) 6.8 (5.2-10.8)* 7 (15.9) 5.5 (2.1-14.7) 7 (15.9) 5.9 (2.1-14.7)
Grade       
   Poor/Undifferentiated 11 (44.0) 5.7 (4.2-11.3) 9 (36) 5.8 (1.01-37.2) 12 (48.0) 5.9 (1.3-37.2)
   Well/Moderate 11 (13.1) 5.0 (1.2-10.8) 11 (13.1) 5.5 (1.6-14.7) 14 (16.7) 5.2 (1.2-14.7)
Nodal Involvement       
   Yes 20 (39.2) 5.1 (1.8-11.3) 17 (33.3) 5.5 (1.01-37.2) 21 (41.2) 5.8 (4.2-37.2)*
   No 2 (3.5) 2.6 (1.2-4.1)3 3 (5.2) 2.1 (1.3-14.7) 5 (8.6) 2.1 (1.2-14.7)*
HPV DNA       
   High-Risk 20 (66.7) 5.0 (1.2-11.3) 16 (53.3) 5.7 (1.01-37.2) 21 (70.0) 5.7 (1.2-37.2)
   Negative 2 (2.5) 7.1 (5.2-9.0) 4 (5.1) 3.0 (1.3-14.7) 5 (6.3) 5.2 (1.3-14.7)
  1. 1OD = optical density; 2All OD ratio tests were two-group comparisons: reference for partners was 0-2, reference for alcohol and tobacco was 'never', reference for tumor site was 'oropharynx'; 3Mean and range; *p-value for median difference between groups was ≤ 0.05.